Ophidion

Ophidion is a private, preclinical-stage biotechnology company pioneering a novel CNS carrier technology to noninvasively deliver therapeutics across the blood-brain barrier. Founded in 2018, the company is leveraging its platform to build a pipeline targeting neurodegenerative diseases, a major unmet medical need. The leadership team comprises seasoned pharmaceutical executives with deep experience in neuroscience, drug development, and business strategy, positioning the company to advance its platform and therapeutic programs.

Ophidion CNS Carrier Technology (OCCT): A proprietary, non-invasive platform using a receptor-mediated 'Trojan horse' approach to deliver a broad range of therapeutics (siRNAs, ASOs, antibodies, peptides) across the blood-brain barrier via IV or subcutaneous administration.

Ophidion competes with other companies developing BBB-crossing technologies, including those using receptor-mediated transport (e.g., bioconjugates), focused ultrasound, and nanoparticle systems. It also competes broadly with all biopharma companies developing neurodegenerative disease therapies, where delivery remains a primary bottleneck.